Adherium announces production & market release of new, next-gen sensors
Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote patient monitoring and data management solutions, is pleased to announce that it has commenced production and market release of the new, next generation Hailie® sensors with physiological parameters connecting GlaxoSmithKline (GSK) Ventolin®, Advair®/Flixotide® and Flovent®/Seretide® inhalers for monitoring Asthma and Chronic Obstructive Pulmonary Disease (COPD).
Mr Rick Legleiter, Adherium Chief Executive Officer, commented, “Purchase orders are in house with a fast-growing pipeline for our sensors with expanded data capabilities. This latest market release expands the portfolio by adding more inhalers covered with physiological parameter capabilities. I am excited for patients and for commercial focus with our business partners.”
Preventable hospitalisations cost the US health system alone US$34 billion annually. The Hailie platform’s physiological parameters offer enhanced monitoring services for patients with severe, uncontrolled, and difficult to treat respiratory diseases, providing opportunities to improve patient management, increase responsiveness to exacerbations and ultimately reduce hospitalisations. The market adoption of digital health innovations in the US is encouraged by the Centers for Medicare & Medicaid Services (CMS) who provide reimbursement for remote patient monitoring.
Hailie enables doctors to bill for long-term, remote patient management under established US reimbursement codes. Adherium gets paid for sensor sales and by receiving monthly, per patient fees for generating and transmitting respiratory data.
“Ineffective usage and adherence tragically limit up to 90% of patients from receiving the full benefit of their transformative inhaled medications. With our groundbreaking Hailie sensors, we’re championing proactive self-care, pioneering data-driven remote monitoring, and propelling enhanced outcomes at unparalleled lower cost, said Francis White, Adherium’s VP Global Business Development.
Supported by US 510(k), Australia TGA and UK MHRA market clearances, this market release expands Adherium’s Hailie sensor portfolio in the US, as well as across other regions including Australia, and the UK. Adherium offers the only 510(k) cleared sensor technology on the market today with respiratory flow data, in addition to the traditional adherence measurement at the time of medication use, for Asthma and COPD inhaler medications.
These new sensors continue Adherium’s focus on physiological data capture including inhalation duration and peak inhalation flow, alongside traditional Asthma/COPD medication adherence monitoring. This is an important step in enabling Asthma and COPD sufferers to receive increased support and assisting them with their medication usage and disease management, while at the same time enhancing our remote patient monitoring capability via the Adherium Hailie Portal.